Evidence map›Paper›PMID 37644614›Full record

ArticleSystematic reviews2023

Proximal gastrectomy and double-tract reconstruction vs total gastrectomy in gastric and gastro-esophageal junction cancer patients - a systematic review and meta-analysis protocol (PROSPERO registration number: CRD42021291500).

Julian Hipp, Jasmina Kuvendjiska, Verena Martini, Hans Christian Hillebrecht, Stefan Fichtner-Feigl, Markus K Diener

Open access · goldAbstract read
In one paragraph

Article in Systematic reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Julian HippDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine-University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.ORCID http://orcid.org/0000-0001-9291-9695
Jasmina KuvendjiskaDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine-University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Verena MartiniDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine-University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Hans Christian HillebrechtDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine-University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Stefan Fichtner-FeiglDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine-University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
Markus K DienerDepartment of General and Visceral Surgery, Medical Center-University of Freiburg, Faculty of Medicine-University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. markus.diener@uniklinik-freiburg.de.
University of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Germany and Western Europe, gastroesophageal junction cancer (AEG) and proximal gastric cancer are currently treated with (transhiatal-extended) total gastrectomy (TG) according to the latest treatment guidelines. TG leads to a severe and long-lasting impairment of postoperative health-related quality of life (HRQoL) of the treated patients. Recent studies have suggested that HRQoL of these patients could be improved by proximal gastrectomy with double-tract reconstruction (PG-DTR) without compromising oncologic safety. Our aim is therefore to conduct a randomized controlled non-inferiority trial comparing PG-DTR with TG in AEG II/III and gastric cancer patients with overall survival as primary endpoint and HRQoL as key secondary endpoint.

methodsThis protocol is written with reference to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P 2015) statement. We will conduct searches in the electronic databases MEDLINE, Web of Science Core Collection, ScienceDirect, and Cochrane Library. We will also check references of relevant studies and perform a cited reference research. Titles and abstracts of the records identified by the searches will be screened, and full texts of all potentially relevant articles will be obtained. We will consider randomized trials and non-randomized studies. The selection of studies, data extraction, and assessment of risk of bias of the included studies will be conducted independently by two reviewers. Meta-analysis will be performed using RevMan 5.4 (Review Manager (RevMan) Version 5.4, The Cochrane Collaboration). DISCUSSION: This systematic review will identify the current study pool concerning the comparison of TG and PG-DTR and help to finally refine the research questions and to allow an evidence-based trial design of the planned multicenter randomized-controlled trial. ETHICS AND DISSEMINATION: Ethical approval is not required for this systematic review. Study findings will be shared by publication in a peer-reviewed journal. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42021291500.

Indexed as

Esophageal NeoplasmsStomach NeoplasmsEsophagogastric JunctionGastrectomyHumansMeta-Analysis as TopicMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicSystematic Reviews as TopicDouble-tract reconstructionEsophagogastric junction cancerGastrectomyGastric cancerMeta-analysisOncologic surgeryProtocolProximal gastrectomySystematic reviewVisceral surgery

Identifiers

PMID37644614
PMCPMC10463580
OpenAlexW4386251935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.